TOP TIERMARKET NEWSWIRE

News & sentiment

ALNYLAM PHARMACEUTIC (ALNY) — News & AI sentiment

ALNYLAM PHARMACEUTIC (ALNY) news roundup. 6 stories in the past week, 23 over 30 days. Average 30-day sentiment is 53.9/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $399K — net selling of $399K. US House Periodic Transaction Reports (90-day window): 3 purchases (~$24K) and 2 sales (~$41K). Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

6

avg sentiment 66.3/100

30d stories

23

avg sentiment 53.9/100

Insider net (90d)

$399K

0 buys · 1 sells

Congress (90d)

1

3 buys · 2 sells

ALNY news in the last 24 hours, 7 days, 30 days and 90 days

How much ALNY coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ALNY stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	6	66.3/100	ALNY headlines →
Last 30 days	23	53.9/100	ALNY headlines →
Last 90 days	83	52.1/100	ALNY headlines →

Latest stories on ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Seeking Alpha58 · neutralproduct/pr

1d ago

Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case

Seeking Alpha67 · bullishanalyst

2d ago

Raymond James reiterates Alnylam stock Strong Buy on positive trial data

Investing.com Analyst Ratings67 · bullishanalyst

5d ago

Alnylam sees promising early-stage data for Huntington's asset brezosiran

Seeking Alpha74 · bullishproduct/pr

5d ago

Alnylam reports ALN-HTT02 clinical trial results

The Fly58 · neutralproduct/pr

5d ago

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

StockTitan74 · bullishproduct/pr

5d ago

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

The Motley Fool63 · neutralgeneral

Oct 21

Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?

Yahoo Finance63 · neutralgeneral

Oct 20

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

StockTitan50 · neutralearnings

Oct 15

Alnylam assumed with a Buy at UBS

The Fly63 · neutralanalyst

Oct 15

Alnylam price target lowered to $253 from $256 at Wells Fargo

The Fly42 · neutralanalyst

Oct 14

Alnylam price target lowered to $320 from $340 at Citi

The Fly38 · neutralanalyst

Oct 14

Alnylam vs. Ionis: Here's the Better Bad-News Buy

The Motley Fool63 · neutralanalyst

Oct 10

Alnylam price target lowered to $336 from $346 at BofA

The Fly38 · neutralanalyst

Oct 9

Alnylam price target lowered to $345 from $350 at RBC Capital

The Fly42 · neutralanalyst

Oct 8

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

GlobeNewswire42 · neutralgeneral

Oct 5

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

GlobeNewswire42 · neutralgeneral

Oct 5

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

GlobeNewswire34 · bearishgeneral

Oct 2

Cantor Fitzgerald reiterates Neutral rating on Alnylam stock

Investing.com Analyst Ratings50 · neutralanalyst

Sep 30

Alnylam price target lowered to $369 from $375 at JPMorgan

The Fly48 · neutralanalyst

Sep 30

Alnylam announces launch of AMVUTTRA ‘Play by Play’ initiative

The Fly56 · neutralproduct/pr

Sep 29

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform

Seeking Alpha58 · neutralgeneral

Sep 28

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

The Motley Fool58 · neutralanalyst

Sep 28

Alnylam Needs Stronger Amvuttra Execution To Justify More Upside

Seeking Alpha56 · neutralanalyst

Sep 26

H.C. Wainwright reiterates Alnylam stock rating on cardiovascular trial outlook

Investing.com Analyst Ratings56 · neutralanalyst

Sep 21

Open ALNY in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →